NYSE · Health care

Theriva Biologics, Inc. (TOVX)

It posted a net loss of $13.1M. In fiscal 2025 capital spending exceeded operating cash flow by $16.7M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Price

$0.22

-4.30% on the day · September 25, 2026

52-week range $0.16 to $0.86

Market cap

$10.1M

What Theriva Biologics, Inc. does

Theriva Biologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker TOVX.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$24.1M	-$25.2M	-$2.08	-$16.7M
2024	n/a	-$26.3M	-$25.7M	-$19.03	-$16.9M
2023	n/a	-$21.4M	-$18.3M	-$28.48	-$19.2M
2022	n/a	-$21.6M	-$19.7M	-$32.73	-$19.2M
2021	n/a	-$14.3M	-$14.3M	-$47.47	-$12.9M
2020	n/a	-$10.2M	-$10M	-$164.88	-$12.2M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 17, 2026.

Estimated from its filing rhythm: about 98 days after its last report of August 11, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Theriva Biologics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 24, 2026
Employee stock plan registration S-8
August 11, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.07 versus -$1.93.
August 11, 2026
Quarterly results 8-K
August 6, 2026
Investor disclosure 8-K
August 4, 2026
Executive or director change 8-K
July 7, 2026
Investor disclosure 8-K
June 29, 2026
Proxy statement DEF 14A
June 29, 2026
Annual report to shareholders ARS
June 18, 2026
Preliminary proxy statement PRE 14A
June 11, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on January 6, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about TOVX

What does Theriva Biologics, Inc. do?

Theriva Biologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker TOVX.

Is Theriva Biologics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $13.1M.

When did Theriva Biologics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from August 24, 2026.

Similar companies

Compare TOVX with

Compare TOVX with any company

Follow TOVX

Get an email when Theriva Biologics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TOVX: get an email when it files

Where the numbers come from

Financial figures are the values Theriva Biologics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.